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The relationship between serum uric acid levels and a
variety of cardiovascular conditions have been reported
since the early 1960s [1]. Metabolic syndrome is defined
by a clustering of risk factors for cardiovascular disease
[2,3]. An increasing prevalence of metabolic syndrome
has been reported in Korea [4,5]. The higher serum uric
acid level of hyperuricemia has been associated with
metabolic syndrome in studies of health screenees [3,6-
9] and in nationwide surveys [10,11]. However, the
direct association between uric acid levels and metabolic
syndrome remains controversial, and most clinical
guidelines do not recommend treating asymptomatic
hyperuricemia [12]. Moreover, serum uric acid levels
within a normal to high range have not been fully
evaluated in association with metabolic syndrome.
Therefore, we evaluated the association of serum uric
acid levels with metabolic syndrome in a rural
population in Korea.
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I. Participants
This study is a cross-sectional analysis of baseline data
of a community-based prospective cohort, which started
in 2006 on Kanghwa Island, South Korea. This analysis
enrolled participants who attended a health examination
in 2008 or 2009 because serum uric acid testing has been
available since 2008. Among the initial total of 2396
participants, we excluded 8 participants because their
uric acid levels were not measured. An additional 8
participants were excluded for the following reasons:
absence of systolic blood pressure (SBP) or <60 mmHg,
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Objectives: Serum uric acid levels have been reported to be associated with a variety of cardiovascular conditions.
However, the direct association between uric acid levels and metabolic syndrome remains controversial. Thus, we
evaluated the association of serum uric acid levels and metabolic syndrome in a community-based cohort study in Korea. 
Methods: We performed cross-sectional analysis of baseline data of 889 males and 1491 females (aged 38 to 87) who
participated in baseline examinations of the Korean Genome and Epidemiology Study: Kanghwa study. Blood samples
were collected after at least an 8 hour fast. Uric acid quartiles were defined as follows: <4.8, 4.8-<5.6, 5.6-<6.5, 6.5
mg/dL in males; and <3.8, 3.8-<4.3, 4.3-<5.1, 5.1 mg/dL in females. Metabolic syndrome was defined by the National
Cholesterol Education Program Adult Treatment Panel III Criteria with adjusted waist circumference cutoffs (90 cm for
males; 80 cm for females). The association between serum uric acid quartiles and metabolic syndrome was assessed
using multivariate logistic regression. 
Results: The odds ratio for having metabolic syndrome in the highest versus lowest quartiles of serum uric acid levels
was 2.67 (95% confidence interval [CI], 1.60 to 4.46) in males and 2.14 (95% CI, 1.50 to 3.05) in females after adjusting
for age, smoking, alcohol intake, body mass index, total cholesterol, HbA1c, albumin, Ǳ -glutamyltransferase, blood urea
nitrogen, and log C-reactive protein. The number of metabolic abnormalities also increased gradually with increasing
serum uric acid levels (adjusted p for trend <0.001 in both sexes). 
Conclusions: Higher serum uric acid levels are positively associated with the presence of metabolic syndrome in Korean
males and females.
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Table 1. Characteristics of the participants according to serum uric acid level
Data were expressed as meanSD or number (%).
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein.
1 Chi-squared test.
Variables
Serum uric acid quartile (mg/dL)
p-value
<4.8 (n=197) 4.8-<5.6 (n=225) 5.6-<6.5 (n=230) 6.5 (n=237)
Male (n=889)
Age (y)
Body mass index (kg/m
2)
Waist circumference (cm)
SBP (mmHg)
DBP (mmHg)
Total protein (g/dL)
Albumin (g/dL)
Aspartate aminotransferase (IU/L)
Alanine transaminase (IU/L)
Ǳ -glutamyltransferase (IU/L)
Total bilirubin (mg/dL)
Blood urea nitrogen (mg/dL)
Creatinine (mg/dL)
HDL cholesterol (mg/dL)
Total cholesterol (mg/dL)
Triglycerides (mg/dL)
Fasting glucose (mg/dL)
HbA1c (%)
Insulin (uIU/mL)
C-reactive protein (mg/dL)
Smoking status
Non-smoker
Current smoker
Drinking status
Non-drinker
Current drinker
061.17.9
023.83.0
085.67.8
120.716.6
075.19.3
007.40.4
004.40.3
025.911.1
025.314.6
044.065.6
00.940.33
016.34.0
00.990.12
043.110.8
189.032.8
140.2110.9
101.827.1
005.81.1
007.63.1
001.95.1
144 (73.10)
53 (26.90)
105 (53.30)
92 (46.70)
059.38.3
024.02.7
086.27.4
122.615.3
077.09.4
007.40.4
004.50.2
027.015.4
027.023.6
042.185.2
00.970.35
016.44.7
01.020.12
042.99.8
190.131.9
157.0119.5
098.220.5
005.70.8
008.03.5
001.65.0
163 (72.44)
62 (27.56)
87 (38.67)
138 (61.33)
058.87.5
024.72.7
087.56.8
121.316.1
077.89.7
007.50.4
004.50.2
026.58.6
027.313.2
041.542.7
00.960.38
016.64.3
01.050.13
042.49.8
194.634.2
159.090.1
096.718.4
005.60.8
008.13.3
001.63.6
166 (72.17)
64 (27.83)
89 (38.70)
141 (61.30)
058.48.5
025.32.9
089.17.2
123.317.0
078.69.1
007.60.4
004.50.3
029.514.4
030.117.3
060.386.9
00.970.39
017.25.0
01.110.24
040.49.2
189.533.8
198.7139.5
099.119.1
005.70.8
008.63.2
001.62.9
180 (75.95)
57 (24.05)
72 (30.38)
165 (69.62)
0.003
<0.001
<0.001
0.320
0.001
<0.001
0.008
0.020
0.040
0.010
0.890
0.130
<0.001
0.003
0.250
<0.001
0.120
0.100
0.020
0.910
0.78
10
0.001
1
Variables
Serum uric acid quartile (mg/dL)
p-value
<3.8 (n=368) 3.8-<4.3 (n=327) 4.3-<5.1 (n=414) 5.1 (n=382)
Female (n=1491)
Age (y)
Body mass index (kg/m
2)
Waist circumference (cm)
SBP (mmHg)
DBP (mmHg)
Total protein (g/dL)
Albumin (g/dL)
Aspartate aminotransferase (IU/L)
Alanine transaminase (IU/L)
Ǳ -glutamyltransferase (IU/L)
Total bilirubin (mg/dL)
Blood urea nitrogen (mg/dL)
Creatinine (mg/dL)
HDL cholesterol (mg/dL)
Total cholesterol (mg/dL)
Triglycerides (mg/dL)
Fasting glucose (mg/dL)
HbA1c (%)
Insulin (uIU/mL)
C-reactive protein (mg/dL)
Smoking status
Non-smoker
Current smoker
Drinking status
Non-drinker
Current drinker
056.38.1
023.93.0
085.48.9
118.417.7
070.210.1
007.40.4
004.50.2
022.87.7
020.311.9
018.622.2
00.840.30
014.53.9
00.820.10
047.210.7
199.637.2
121.872.0
094.024.3
005.60.8
008.23.0
001.33.8
363 (98.64)
5 (1.36)0
274 (74.46)
94 (25.54)
056.18.1
024.52.9
087.08.0
118.116.7
071.39.2
007.40.4
004.50.2
022.35.9
019.58.2
017.513.5
00.830.30
015.23.9
00.830.09
046.010.4
197.832.7
121.159.3
094.718.2
005.60.9
008.43.4
001.24.2
324 (99.08)
3 (0.92)0
253 (77.37)
74 (22.63)
057.28.0
024.93.3
087.97.9
119.816.7
072.19.8
007.50.4
004.50.2
023.56.4
021.29.5
020.736.6
00.830.43
015.24.2
00.850.09
044.19.9
202.034.2
145.282.8
095.916.8
005.70.7
008.83.5
001.42.4
408 (98.55)
6 (1.45)0
310 (74.88)
104 (25.12)
059.08.0
025.93.5
090.18.7
123.118.6
073.09.6
007.50.4
004.50.2
024.48.2
023.212.2
027.258.6
00.800.28
016.34.4
00.920.16
043.19.9
206.839.1
166.089.7
097.727.9
005.91.0
009.63.9
001.82.4
368 (96.34)
14 (3.66)0
281 (73.56)
101 (26.44)
<0.001
<0.001
<0.001
<0.001
0.001
<0.001
0.010
0.001
<0.001
0.002
0.300
<0.001
<0.001
<0.001
0.006
<0.001
0.110
<0.001
<0.001
0.100
0.03
1
0.69
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absence of diastolic blood pressure (DBP) or <40
mmHg, absence of pulse rates or >700 beats/min or <30
beats/min, and triglycerides >1500 mg/dL. A final total
of 2380 participants (male 889, female 1491) were
enrolled in this study. All participants signed written
informed consent forms, and the Institutional Review
Board approved the study protocol.
II. Definition of Metabolic Syndrome
Metabolic syndrome was determined according to the
criteria of the National Cholesterol Education Program
Adult Treatment Panel III, except for waist circumference,
where the Asian cutoffs were used. Thus, metabolic
syndrome was defined as the presence of three or more
of the following five criteria: 1) waist circumference 
90 cm in males and 80 cm in females, 2) triglycerides
150 mg/dL or under treatment for elevated triglycerides,
3) high-density lipoprotein (HDL)-cholesterol <40
mg/dL in males and <50 mg/dL in females or under
treatment for reduced HDL, 4) SBP 130 mmHg or
DBP 85 mmHg or under treatment for hypertension,
and 5) fasting glucose 100 mg/dL or under treatment
for elevated glucose [13].
III. Measuring Study Variables
Detailed methods for the measurements used in the
Korean Genome and Epidemiology Study: Kanghwa
study were previously reported elsewhere [14-16].
Trained personnel measured the anthropometric
variables according to the written protocol. Waist
circumference was measured on a horizontal plane
midway between the inferior margin of the ribs and the
superior border of the iliac crest using a tape measure
(SECA-200; SECA, Hamburg, Germany). Resting blood
pressure was measured twice with at least 5 minute
intervals using an automatic sphygmomanometer
(Dinamap 1846 SX/P; GE Healthcare, Waukesha, WI,
USA). If the difference between the first and second
measurement was more than 10 mmHg, then repeated
measurements were performed. The average of the last
two measurements was used for the analysis. Blood
samples were collected from the antecubital vein after at
least an 8 hour fast. Enzymatic methods were applied to
measure fasting plasma glucose, serum uric acid,
triglycerides, total cholesterol, and HDL cholesterol
(ADVIA 1650; Siemens Healthcare Diagnostics Inc.,
Deerfield, IL, USA). Serum uric acid levels were
divided into separate quartiles for males and females.
Sex-specific serum uric acid quartiles were used as
follows: <4.8, 4.8-<5.6, 5.6-<6.5, 6.5 mg/dL in
males; and <3.8, 3.8-<4.3, 4.3-<5.1, 5.1 mg/dL in
females.
IV. Statistical Analysis
Prior to performing statistical analysis, the levels of
triglycerides, fasting glucose, and C-reactive protein
were log-transformed because of the skewed
distribution. The differences between the investigated
variables’ means according to sex-specific serum uric
acid quartiles were tested using the chi-squared test and
analysis of variance. The relationships between serum
uric acid levels and other variables were assessed using
the Pearson’s correlation coefficients. The trend test was
performed to determine the trends with the number of
metabolic abnormalities and prevalence of metabolic
syndrome according to the serum uric acid quartile. The
association between the sex-specific serum uric acid
quartile and metabolic syndrome were tested using
multivariate logistic regression analysis. We calculated
the unadjusted and adjusted odds ratios (ORs) using the
lowest quartile as the reference. In the adjusted model,
we controlled age, smoking status (current smoker vs.
others), alcohol intake (current drinker vs. others), body
mass index (BMI), total cholesterol, HbA1c, albumin,
blood urea nitrogen (BUN), Ǳ -glutamyltransferase, and
log C-reactive protein. Controlled variables were
selected based on the following criteria. Age, smoking
status, alcohol intake, and BMI were first selected after
the literature had been reviewed, whereas sex was
stratified. The variables that did not exceed 0.3 of the
correlation p-value were then contained, after which the
stepwise method was used. BUN was then additionally
adjusted as a marker of kidney function. All statistical
analyses were performed using SAS version 9.2.0 (SAS
Inc., Cary, NC, USA). We used a two-tailed test, and a
value of p<0.05 was considered to be statistically
significant. 
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The characteristics of the study participants are
summarized in Table 1 according to the sex-specific
quartile of the serum uric acid levels. The age
distribution was different for males and females. The
higher quartiles of serum uric acid levels tended to be
associated with younger ages in males, but older ages in
females.  +V.J-FFFUBM
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I. Relationship Between Serum Uric Acid
Level and Investigated Variables
Serum uric acid levels had positive correlations with
waist circumference, BMI, SBP, total protein, albumin,
aspartate aminotransferase, alanine aminotransferase, Ǳ -
glutamyltransferase, BUN, creatinine, log triglycerides,
fasting insulin, and log C-reactive protein and an inverse
correlation with HDL-cholesterol level in both sexes
(Table 2). Age was negatively correlated with serum uric
acid in males, but positively correlated in females. The
pulse rate was positively correlated with serum uric acid
in males (coefficient 0.087, p-value 0.010). However,
total cholesterol, fasting glucose, and HbA1c were
positively correlated with serum uric acid in females. 
II. Association Between Serum Uric Acid
Quartiles and Metabolic Syndrome
The number of metabolic abnormalities according to
the serum uric acid quartile is shown in Figure 1. The
number of metabolic syndrome components increased
gradually with increasing serum uric acid quartile before
(p for trend <0.001 in both sexes) and after adjustment
(p for trend <0.001 in both sexes). The prevalence of
metabolic syndrome also increased gradually with an
increasing serum uric acid quartile before (p for trend
<0.001 in both sexes) and after adjustment (p for trend
<0.001 in both sexes) in Figure 2.
The highest quartile had a higher OR for metabolic
syndrome than the lowest quartile after adjusting for age,
smoking, alcohol intake, BMI, total cholesterol, HbA1c,
albumin, BUN, Ǳ -glutamyltransferase, and log C-
reactive protein in both sexes (Table 3). Presence of
metabolic syndrome significantly increased in the
second, third, and fourth quartiles of serum uric acid
levels in males, but at the third and fourth quartiles of
serum uric acid levels in females. 
%*4$644*0/
We evaluated the associations of serum uric acid levels
with metabolic syndrome in a rural population in Korea.
Table 2. Correlation between serum uric acid and investigated variables
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein.
Variables
Male Female
Pearson’s coefficients p-value Pearson’s coefficients p-value
Age (y)
Body mass index (kg/m
2)
Waist circumference (cm)
SBP (mmHg)
DBP (mmHg)
Total protein (g/dL)
Albumin (g/dL)
Aspartate aminotransferase (IU/L)
Alanine transaminase (IU/L)
Ǳ -glutamyltransferase (IU/L)
Total bilirubin (mg/dL)
Blood urea nitrogen (mg/dL)
Creatinine (mg/dL)
Total cholesterol (mg/dL)
HDL-cholesterol (mg/dL)
Log (triglycerides in mg/dL)
Log (fasting glucose in mg/dL)
HbA1c (%)
Insulin (uIU/mL)
Log (C-reactive protein in mg/L)
-0.096 
0.189 
0.163 
0.086 
0.005 
0.192 
0.086 
0.116 
0.104 
0.095 
0.050 
0.103 
0.323 
0.001 
-0.119 
0.217 
-0.039 
-0.052 
0.107 
0.102 
0.004
<0.001
<0.001
0.010
0.950
<0.001
0.010
0.001
0.002
0.005
0.140
0.002
<0.001
0.980
<0.001
<0.001
0.250
0.120
0.001
0.002
0.138 
0.226 
0.207 
0.053 
0.083 
0.155 
0.069 
0.102 
0.113 
0.134 
-0.046 
0.181 
0.349 
0.102 
-0.154 
0.252 
0.070 
0.101 
0.164 
0.239 
<0.001
<0.001
<0.001
0.040
0.140
<0.001
0.008
<0.001
<0.001
<0.001
0.070
<0.001
<0.001
<0.001
<0.001
<0.001
0.007
<0.001
<0.001
<0.001
Table 3. The association between serum uric acid
level quartiles and metabolic syndrome 
1 Adjusted for age, smoking, alcohol intake, body mass index, total cholesterol,
HbA1c, albumin, Ǳ -glutamyltransferase, blood urea nitrogen, and 
C-reactive protein (log-transformed).
Serum uric acid
quartile (mg/dL)
Odds ratio (95% confidence interval)
for metabolic syndrome
Unadjusted Adjusted
1
Male
1st (<4.8)
2nd (4.8-<5.6)
3rd (5.6-<6.5)
4th (6.5)
Female
1st (<3.8)
2nd (3.8-<4.3)
3rd (4.3-<5.1)
4th (5.1)
1.00 
1.38 (0.91, 2.09)
1.70 (1.13, 2.56)
2.67 (1.78, 4.00)
1.00 
0.99 (0.73, 1.34)
2.00 (1.50, 2.66)
3.32 (2.46, 4.48)
1.00 
1.72 (1.03, 2.88)
1.94 (1.17, 3.22)
2.67 (1.60, 4.46)
1.00 
0.86 (0.61, 1.23)
1.62 (1.16, 2.25)
2.14 (1.50, 3.05)4FSVN6SJD"DJEBOE.FUBCPMJD4ZOESPNF
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We found that higher serum uric acid levels, even within
the normal ranges, were associated with an increased
prevalence of metabolic syndrome in both sexes even
after adjusting for confounding factors. 
Uric acid is the final product of purine metabolism and
is excreted via the urine in higher primates [17,18].
Particularly in humans, over half of the antioxidant
capacity of blood plasma comes from uric acid [18].
Reports have shown that serum uric acid levels have
been increasing since 1960s in the US population, and
this is possibly associated with the cardiovascular
disease epidemic that has occurred over the last 100
years [19]. There is increasing evidence that uric acid
plays a role in the development of metabolic syndrome.
Animal studies have shown that decreasing uric acid
levels may prevent or reverse the course of metabolic
syndrome. One of the possible biological mechanisms is
related to insulin-stimulated endothelial nitric oxide
synthesis. Insulin-stimulated endothelial nitric oxide
synthase (eNOS) regulates blood flow, influencing
glucose uptake in skeletal muscle [1]. Animal studies
have also shown that hyperuricemia caused by eNOS,
Figure 1. The number of metabolic abnormalities according to the serum uric acid quartile.
1 Adjusted for age, smoking, alcohol intake, body mass index, total cholesterol, HbA1c, albumin, blood urea nitrogen, Ǳ -glutamyltransferase, and log CRP.
2 Number of following metabolic abnormalities: 1) waist circumstance 90 cm in male and 80 cm in female, 2) triglycerides 150 mg/dL or under treatment for
elevated triglycerides, 3) high-density lipoprotein (HDL)-cholesterol <40 mg/dL in male and <50 mg/dL in female or under treatment for reduced HDL, 4) SBP 130
mmHg or DBP 85 mmHg or under treatment for hypertension, 5) fasting glucose 100 mg/dL or under.
Figure 2. Prevalence of metabolic syndrome according to the serum uric acid quartile
1 Adjusted for age, smoking, alcohol intake, body mass index, total cholesterol, HbA1c, albumin, blood urea nitrogen, Ǳ -glutamyltransferase, and log CRP. +V.J-FFFUBM
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and impaired eNOS, are associated with metabolic
syndrome [1,20,21]. Another study showed that
treatment for hyperuricemia patients improved
endothelial dysfunction [1,22]. Therefore, we suggest
that hyperuricemia could induce endothelial cell
dysfunction and contribute to the development of
metabolic syndrome. Another possible mechanism is
related to inflammation and oxidative stress. Uric acid in
adipocytes of obese mice induced inflammatory
oxidative changes: hence the resulting development of
metabolic syndrome [23-25]. 
Our findings are, in general, consistent with previous
reports [3,6-11], but can be distinguished from them.
First, our study population consisted of community-
dwellers rather than institutionalized patients or health
screenees, thereby potentially reducing selection bias.
Second, our study showed that higher serum uric acid
levels, even within the normal ranges, were associated
with metabolic syndrome. Serum uric acid levels ranged
from 0.6 to 10.8 mg/dL in our participants. Most
previous studies have investigated the association
between frank hyperuricemia (defined as more than 6
mg/dL in females and more than 7 mg/dL in males)
[1,9,10,26-28] with metabolic syndrome. Third, we
investigated the association between serum uric acid
level and metabolic syndrome in males and females
separately, and the strength of association differed
between sexes (Table 3). Fasting glucose and HbA1c
were positively correlated with serum uric acid only in
females, but not in males (Table 2). We cannot clearly
explain these differences by sex; however, one of the
possible explanations for the differences might be a non-
linear relationship between uric acid level and glucose
metabolism. Serum uric acid levels have different
distributions in males and females. The range of the
second quartile in males (4.8-<5.6 mg/dL) is similar to
that of the third quartile in females (4.3-<5.1 mg/dL).
Moreover, there might be different distributions of serum
uric acid levels for men and women with diabetes,
prediabetes, and using anti-diabetic medication. If serum
uric acid levels have non-linear relationships with
diabetes or metabolic syndrome, then the direction and
strength of association could be different for males and
females. A previous study reported an inverse U-shaped
association between fasting glucose and uric acid levels;
fasting glucose levels lower than 8.0 mmol/L were
positively associated with uric acid, but glucose levels
higher than 8.0 mmol/L were inversely associated [29]. 
Because this study is limited due to its cross-sectional
nature, we could not assess temporal relationships. It is
also possible that residual or unmeasured confounding
variables may exist. Some information was unavailable
from the data used in this study, such as history of gout
or kidney diseases, which might have influenced the
serum uric acid levels. Therefore, we adjusted for BUN
as an alternative marker of kidney function. However,
further prospective investigations are required to fully
understand the causal relationship between serum uric
acid levels and the development of metabolic syndrome. 
Our results suggest that individuals with high normal
uric acid levels or asymptomatic hyperuricemia are at
risk of metabolic syndrome. Intensive lifestyle modifi-
cations may be required for such individuals. Currently,
most health screening examinations include a serum uric
acid test, but physicians do not pay attention to uric acid
levels unless the screenees have symptoms of gout.
Physicians should explain the risks of metabolic
syndrome or cardiovascular disease to individuals with
high uric acid levels and recommend lifestyle modifi-
cations or consider preventive medical intervention.
In conclusion, higher serum uric acid levels are
positively associated with the presence of metabolic
syndrome in Korean males and females. 
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